Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Liabilities and Shareholders Equity of $624.4 million for Q2 2026, down 6.82% year-over-year from $670.1 million in Q2 2025, and down 3.31% quarter-over-quarter from $645.8 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $624.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity fell 6.82% year-over-year to $624.4 million; the TTM figure through Jun 2026 stood at $2.6 billion (down 5.83% YoY), while the FY2025 annual figure was $670.8 million, down 2.13% from the prior year.
- Liabilities and Shareholders Equity eased to $624.4 million in Q2 2026 per AMRN's latest filing, from $645.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $973.7 million in Q1 2022 and bottomed at $624.4 million in Q2 2026.
- Historically, Liabilities and Shareholders Equity has averaged $782.5 million across 5 years, with a median of $795.0 million in 2024.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 17.6% — and 2026, when it fell 1.51%.
- Amarin Corp Plc\Uk's Liabilities and Shareholders Equity stood at $886.2 million in 2022, then slipped by 6.15% to $831.7 million in 2023, then decreased by 17.6% to $685.3 million in 2024, then slipped by 2.13% to $670.8 million in 2025, then retreated by 6.91% to $624.4 million in 2026.
- Business Quant data shows AMRN's Liabilities and Shareholders Equity at $624.4 million in Q2 2026, $645.8 million in Q1 2026, and $670.8 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 624.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 624.40 Mn |
| Mar 31, 2026 | 645.80 Mn |
| Dec 31, 2025 | 670.78 Mn |
| Sep 30, 2025 | 659.81 Mn |
| Jun 30, 2025 | 670.13 Mn |
| Mar 31, 2025 | 655.70 Mn |
| Dec 31, 2024 | 685.35 Mn |
| Sep 30, 2024 | 750.62 Mn |
| Jun 30, 2024 | 799.90 Mn |
| Mar 31, 2024 | 790.01 Mn |
| Dec 31, 2023 | 831.68 Mn |
| Sep 30, 2023 | 839.03 Mn |
| Jun 30, 2023 | 860.02 Mn |
| Mar 31, 2023 | 860.20 Mn |
| Dec 31, 2022 | 886.18 Mn |
| Sep 30, 2022 | 908.30 Mn |
| Jun 30, 2022 | 973.24 Mn |
| Mar 31, 2022 | 973.71 Mn |
| Dec 31, 2021 | 1.07 Bn |
| Sep 30, 2021 | 1.04 Bn |